Provided by Tiger Trade Technology Pte. Ltd.

Orchestra BioMed

5.95
-0.4000-6.30%
Post-market: 5.950.00000.00%19:30 EDT
Volume:421.09K
Turnover:2.52M
Market Cap:356.29M
PE:-5.95
High:6.44
Open:6.40
Low:5.77
Close:6.35
52wk High:6.50
52wk Low:2.66
Shares:59.88M
Float Shares:33.00M
Volume Ratio:1.58
T/O Rate:1.28%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9995
EPS(LYR):-1.1091
ROE:-397.30%
ROA:-45.73%
PB:18.44
PE(LYR):-5.36

Loading ...

Orchestra BioMed President, COO Darren Sherman Disposes of $95,400 in Common Shares

Reuters
·
9 hours ago

Orchestra BioMed Completes Enrollment in BACKBEAT AVIM Trial

TIPRANKS
·
Oct 01

Orchestra BioMed Surpasses Enrollment Target in Backbeat Pivotal Trial of AVIM Hypertension Therapy

Reuters
·
Oct 01

Orchestra Biomed Exceeds Full Enrollment Target in the Backbeat Global Pivotal Trial of Avim Therapy

THOMSON REUTERS
·
Oct 01

Orchestra Biomed - Primary Endpoint Data to be Submitted for Presentation at Cardiovascular Conference in Q2 2027

THOMSON REUTERS
·
Oct 01

Orchestra BioMed Exceeds Full Enrollment Target in the BACKBEAT Global Pivotal Trial of AVIM Therapy

GlobeNewswire
·
Oct 01

Orchestra BioMed Says Investigational AVIM Hypertension Therapy Features in HRX Live Sessions

Reuters
·
Sep 16

Orchestra Biomed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics

THOMSON REUTERS
·
Sep 15

Press Release: Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics

Dow Jones
·
Sep 15

B. Riley Adjusts Orchestra BioMed Price Target to $11 From $10, Maintains Buy Rating

MT Newswires Live
·
Sep 15

Orchestra BioMed Shares Rise After BTIG Upgrade

MT Newswires Live
·
Sep 11

Top Midday Gainers

MT Newswires Live
·
Sep 11

BTIG Upgrades Orchestra BioMed to Buy From Neutral, Price Target is $10

MT Newswires Live
·
Sep 10

Orchestra Biomed Holdings Inc : Btig Raises to Buy from Neutral

THOMSON REUTERS
·
Sep 10

Orchestra BioMed Holdings Price Target Announced at $10.00/Share by BTIG

Dow Jones
·
Sep 10

Top Exec Makes Bold Insider Move at Orchestra BioMed Holdings

TIPRANKS
·
Sep 09

Orchestra BioMed Highlights $500 Million-Plus Annual Royalty Potential from Medtronic-Partnered AVIM Pacemaker Therapy

Reuters
·
Sep 08

Orchestra BioMed CEO, Chair David P. Hochman Buys $47,900 Common Shares

Reuters
·
Sep 08

Orchestra BioMed COO, Director Darren Sherman Disposes of 15,000 Common Shares for $74,100

Reuters
·
Sep 03

Orchestra BioMed Grants 133,000 Inducement Stock Options to Seven New Hires Under 2025 Plan

Reuters
·
Sep 03